June 24, 2013 /PRNewswire/ --
During the Drug Information Association's (DIA) annual meeting today, Veeva Systems previewed its new Veeva Vault Investigator Portal. As a companion product to Vault eTMF, Vault Investigator Portal enables fast collection, sharing and tracking of all investigator content from a single platform. Veeva has specifically designed its new Investigator Portal to speed study start-up by simplifying the overall trial document management process and providing bi-directional, direct access to the eTMF.
Clinical trials are one of the most complex areas of a life sciences company's operations, requiring global reach, coordination and tracking across multiple stakeholders. Investigators and site personnel spend hundreds of hours performing redundant tasks across multiple sponsors and systems. Most trial technologies hinder investigator efficiency and breed frustration. Veeva's cloud-based Vault Investigator Portal orchestrates collaboration with site personnel for more efficient operations.
"Without a doubt, the back and forth between investigators and the CRO or sponsor is causing huge delays in study start-up. Most of these documents are still exchanged as paper, which is slow and adds expense. Sponsors and CROs must find ways to improve the efficiency while protecting the increasingly important site relationship," said
, director of clinical product strategy at Veeva.
Veeva's Vault Investigator Portal helps streamline trials and increase efficiency with features that lessen the workload for sponsors and investigators, including:
- Single source for sponsors, CROs and investigator sites to submit and access documents
- Direct placement of site documents into the eTMF
- Two-way channel for exchanging documents, including safety alerts and site training videos
- Prioritized to-do lists and associated documents packaged and pushed to investigator sites
"With Vault Investigator Portal, sponsors and CROs will benefit from better document tracking and placement into the eTMF," concluded Burton. "The ease-of-use and efficiency for investigators will make working with the sponsor and CRO more attractive, which should keep investigators coming back for trial after trial."